SAN DIEGO — Results from two phase 3 trials offer mixed findings on the potential of experimental Bruton tyrosine kinase (BTK) inhibitors for primary progressive multiple sclerosis (PPMS). Findings ...
In people with primary progressive multiple sclerosis (PPMS), depressive symptoms measured using the Hospital Anxiety and Depression Scale (HADS) predicted subsequent neurologic disability progression ...
The International Progressive MS Alliance has awarded €6.9 million to three global studies aimed at finding solutions for the most common symptoms experienced by people living with progressive MS, ...
An already-approved MS drug can help people with the progressive form of the disease Ocrelizumab delayed disability progression among people randomly assigned to get the drug Up to now, it’s been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results